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https://doi.org/10.1016/j.stemcr.2018.03.003SUMMARYThe derivation ofmicroglia fromhuman stem cells provides systems for understandingmicroglial biology and enables functional studies
of disease-causing mutations. We describe a robust method for the derivation of human microglia from stem cells, which are pheno-
typically and functionally comparable with primary microglia. We used stem cell-derived microglia to study the consequences of
missense mutations in the microglial-expressed protein triggering receptor expressed on myeloid cells 2 (TREM2), which are causal for
frontotemporal dementia-like syndrome and Nasu-Hakola disease. We find that mutant TREM2 accumulates in its immature form,
does not undergo typical proteolysis, and is not trafficked to the plasma membrane. However, in the absence of plasma membrane
TREM2, microglia differentiate normally, respond to stimulation with lipopolysaccharide, and are phagocytically competent.
These data indicate that dementia-associated TREM2mutations have subtle effects on microglia biology, consistent with the adult onset
of disease in individuals with these mutations.INTRODUCTION
Microglia are brain-resident immune cells that perform key
functions during nervous system development and ho-
meostasis. After colonization and maturation in the devel-
oping CNS (Ginhoux et al., 2010; Ransohoff and Cardona,
2010), microglia shape synaptic connections between neu-
rons through synapse pruning and provision of trophic
support (Parkhurst et al., 2013; Schafer et al., 2012). As dy-
namic surveyors of the brain,microglia respond to damage-
and pathogen-associated signals to maintain homeostasis
(Koizumi et al., 2007; Nimmerjahn et al., 2005). In addition
to developmental and homeostatic functions, it is nowwell
established that microglia and associated neuroinflamma-
tion play roles in the progression of a number of neurode-
generative conditions (Perry et al., 2010; Ransohoff, 2016),
with variants or mutations in microglia-expressed genes
linked directly to disease in some cases (Malik et al.,
2015; Paloneva et al., 2002; Sims et al., 2017).While micro-
glial function and dysfunction are involved in many
neurodegenerative conditions, their precise contributions
to disease pathogenesis and progression are not well
understood.
Avenues for the study of microglial biology in disease
have primarily been limited to animal models and immor-
talized cell lines, both of which carry limitations in their
ability to approximate primary human microglia. As
more is understood about the developmental origin and
unique identity ofmicroglia, recent studies have attempted1294 Stem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018 j ª 2018 The
This is an open access article under the CC BY license (http://creativecommoto circumvent this issue by derivingmicroglia from human
induced pluripotent stem cells (iPSCs) in order to study hu-
man and cell-type-specific biology and disease (Abud et al.,
2017; Douvaras et al., 2017; Haenseler et al., 2017; Muffat
et al., 2016; Pandya et al., 2017; Takata et al., 2017). Here
we describe and characterize a robust method for the deri-
vation of microglia from human stem cells, which we then
used to investigate the expressional and functional conse-
quences of mutations in themicroglia-expressed triggering
receptor expressed on myeloid cells 2 (TREM2).
TREM2 is a transmembrane receptor expressed on cells
of myeloid lineage, including osteoclasts and tissue-spe-
cific macrophages such as microglia (Colonna and
Wang, 2016). Homozygous mutations in TREM2 or its
intracellular signaling partner DAP12 are causal for
Nasu-Hakola disease (NHD), which is associated with
bone cysts and an early-onset dementia (Paloneva
et al., 2000, 2002), while a frontotemporal dementia
(FTD)-like syndrome without bone dysfunction has also
been described in patients carrying certain TREM2 muta-
tions (Chouery et al., 2008; Giraldo et al., 2013; Guer-
reiro et al., 2013b). The recent discovery that heterozy-
gous coding variants in TREM2 confer an increased risk
of Alzheimer’s disease (AD) (Guerreiro et al., 2013a; Jin
et al., 2014; Jonsson et al., 2013) has reignited interest
in understanding the role of this receptor in microglial
function.
While the endogenous ligand has not been confirmed,
in vitro studies have demonstrated binding of TREM2 toAuthors.
ns.org/licenses/by/4.0/).
lipoprotein, apolipoprotein, and pathogen- and damage-
associated ligands (Atagi et al., 2015; Bailey et al., 2015;
Daws et al., 2003; Yeh et al., 2016). FTD-like and NHDmu-
tations in TREM2 are described as loss-of-function muta-
tions, as they result in reduced cell surface expression and
ligand binding (Kleinberger et al., 2014; Kober et al.,
2016; Park et al., 2015), while AD-associated variants are
thought to reduce the affinity of TREM2 for its ligands
(Kober et al., 2016; Yeh et al., 2016). Extensive studies
have ascribed a number of functions to TREM2, including
regulation of phagocytosis (Hsieh et al., 2009; Kleinberger
et al., 2014; Takahashi et al., 2005), cytokine release (Ha-
merman et al., 2006; Turnbull et al., 2006), chemotaxis
(Mazaheri et al., 2017), and cell survival (Wang et al.,
2015). While murine models of neurodegenerative disease
indicate that loss or dysfunction of TREM2 signaling im-
pacts uponmicroglial function and disease progression (Ul-
rich et al., 2014; Yuan et al., 2016), the precise role of
TREM2 in microglial biology and the consequences of its
dysregulation in neurodegenerative disease pathogenesis
remain to be determined. Therefore, we used our method
for generating human microglia to study the expression,
cellular localization, and function of TREM2 in microglia
differentiated from iPSCs derived from individuals carrying
TREM2mutations causal for FTD-like syndrome and NHD.RESULTS
Human Stem Cell-Derived Microglia Phenotypically
Resemble Primary Microglia
Microglia differ from other adult tissue-resident macro-
phages in two key ways; firstly, their yolk-sac-derived pro-
genitors arise early in development from a program of
primitive hematopoiesis rather than the later definitive he-
matopoiesis that replaces many tissue-resident macro-
phages in the developed adult (Ginhoux et al., 2010,
2013; Kierdorf et al., 2013; Schulz et al., 2012), and sec-
ondly their transcriptome, reflective of the brain-specific
roles they perform, is distinct from other myeloid cells
(Bennett et al., 2016; Butovsky et al., 2014; Hickman
et al., 2013).
As a starting point for the differentiation ofmicroglia, we
followed an established method for the derivation of prim-
itive macrophage precursors (PMPs) from human pluripo-
tent stem cells (PSCs) (Karlsson et al., 2008; van Wilgen-
burg et al., 2013). It has recently been shown that these
precursors are produced in a Myb-independent manner,
in a pathway closely recapitulating primitive hematopoie-
sis (Buchrieser et al., 2017). Two to three weeks after the
initiation of differentiation, PMPs are produced continu-
ously in suspension, and can be harvested for furthermatu-
ration. The PMP generation phase can continue indefi-nitely and is particularly efficient: in the longest ongoing
differentiation in this study, onemillion PSCs produced be-
tween 23 and 52 million PMPs in seven PSC lines over
80 days, similar to previously reported PMP yields using
the same method (Haenseler et al., 2017; van Wilgenburg
et al., 2013) and microglia yields using a recently described
alternative method (Abud et al., 2017). Using complete
RPMI1640 containing a combination of granulocyte
macrophage colony-stimulating factor (GM-CSF) and
interleukin-34 (IL-34) (Ohgidani et al., 2014), we differen-
tiated PMPs over 6–10 days to produce monocultures
that morphologically resemble microglia (Figure 1A).
Analysis of the proportion of these cells expressing canon-
ical macrophage/microglia markers indicates that this
protocol has a high level of efficiency across genetic back-
grounds, producing cells 95.6% ± 3.6% positive for Iba1
(mean ± SD, n = 6), 95.0% ± 3.6% positive for CD45
(mean ± SD, n = 6), and 99.5% ± 0.4% positive for
TREM2 (mean ± SD, n = 5) (Figure 1B).
To investigate the transcriptional identity of our stem
cell-derived microglia in the context of the wider myeloid
family, we used RNA sequencing (RNA-seq) to compare
the transcriptome of thesemicroglia with a number of pub-
lished datasets: primary ex vivoCNS CD45+microglia/mac-
rophages (Zhang et al., 2016) andmicroglia (Gosselin et al.,
2017), primary microglia and fetal microglia cultured
in vitro for 7–10 days (Abud et al., 2017; Gosselin et al.,
2017), myeloid cells of alternate lineages (monocyte-
derived macrophages (Zhang et al., 2015), CD14+/CD16
monocytes (Abud et al., 2017) and dendritic cells (Abud
et al., 2017)), and iPSC-microglia derived using an alterna-
tive method (Abud et al., 2017) (Figure 2). The recently
published dataset from Gosselin et al. (2017) is a particu-
larly useful addition to our understanding of microglial
identity, as it compares the transcriptomes of freshly iso-
lated ex vivo microglia with the same cells cultured in vitro
for 7–10 days, allowing assessment of how culture environ-
ment alters the transcriptome. PMPs and microglia derived
from three independent differentiations from two genetic
backgrounds were harvested for RNA-seq analysis, in order
to assess reproducibility of the differentiation process both
within and between genetic backgrounds.
At the whole-transcriptome level, PMPs and microglia
generated by the method reported here most closely
resemble cultured primary microglia (Figure 2A). Due to a
lack of unique surfacemarkers, it has historically been diffi-
cult to distinguish microglia from other macrophages and
cells of myeloid lineage. It is only recently that a distinct
transcriptomic profile of microglia has emerged (Bennett
et al., 2016; Butovsky et al., 2014; Hickman et al., 2013). Us-
ing a subset of genes from a recent study that were enriched
in expression in murine microglia compared with other
CNSmyeloid cells (Table S1) (Bennett et al., 2016), we againStem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018 1295
Figure 1. An Efficient Protocol for the Generation of Microglia from Pluripotent Stem Cells
(A) PSCs are differentiated to microglia via embryoid bodies and PMPs. PMPs are produced continuously in culture and are terminally
differentiated into microglia when required.
(B) A high proportion of stem cell-derived microglia express the microglial/macrophage markers Iba1, CD45, and TREM2.
Scale bars represent 100 mm, except PSC and embryoid bodies (1 mm). n = 5–6 biological replicates. Error bars represent SDs.observed that microglia derived from iPSCs using this
method cluster most closely with cultured primary micro-
glia, in addition to monocyte-derived macrophages and
iPSC-microglia derived using an alternative method (Fig-
ure 2B). It is notable that, using this approach, there are
three obvious clusters of cell type: in vitro cultured micro-
glia/macrophages regardless of origin group together,
flanked by a cluster of ex vivomicroglia andmicroglia/mac-
rophages and a separate cluster of primary ex vivo myeloid
cells (dendritic cells and CD14+/CD16 monocytes).
Closer analysis of the expression of microglia ‘‘signature’’
genes (Bennett et al., 2016; Butovsky et al., 2014; Hickman
et al., 2013) indicates that stem cell-derived microglia ex-
press many of these enrichedmicroglial transcripts at com-
parable levels with primary ex vivo and in vitro human mi-
croglia (Figure 2C). In sum, these data indicate a close
similarity of stem cell-derived microglia with primary mi-
croglia at the whole-transcriptome and microglia-specific
transcript level.
Functional Characterization of Human Stem Cell-
Derived Microglia
Microglia are professional phagocytes, able to clear patho-
gens and cellular debris. Using live imaging, we found
that stem cell-derived microglia efficiently phagocytose
bacterial particles, a process attenuated by the actin poly-
merization inhibitor cytochalasin D (Figure 3A). Microglia1296 Stem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018express pattern recognition receptors such as Toll-like re-
ceptors (TLRs) that mediate responses to pathogenic
stimuli. Exposure of microglia to the TLR4 ligand lipo-
polysaccharide (LPS) alone, or in combination with the
immunomodulatory cytokine interferon g, resulted in an
upregulation of the pro-inflammatory cytokines IL-1b
(F(2, 6) = 10.26, p = 0.0116), tumor necrosis factor alpha
(TNF-a) (F(2, 6) = 20.66, p = 0.0020), and IL-6 (F(2, 6) =
8.848, p = 0.0162) over 24 hr (Figure 3B), confirming that
stem cell-derived microglia respond appropriately to path-
ogenic stimuli.
While maintenance of microglia in monoculture is use-
ful for reductionist studies of defined functions, more com-
plex co-culture models of microglia with neurons have the
potential to enable studies of more complex biology,
including microglia migration, interactions with neurons,
and homing to areas of neuronal injury. To explore the abil-
ity of stem cell-derivedmicroglia to invade developing neu-
ral tissues and migrate within them, we added microglia to
preformed 3D cortical organoids that were cultured in
excess of 100 days in vitro. Under these conditions, we
found that stem cell-derived microglia migrated from the
surface deeply into organoids (Figure 3C), and, upon inte-
gration, assumed a pronounced ramified morphology, sur-
viving in those environments for at least several weeks in
the absence of continued supplementation of the medium
with colony-stimulating factors.
Figure 2. The Transcriptome of Human Stem Cell-Derived Microglia Is Similar to Primary Microglia
(A) At the whole-transcriptome level, iPSC-derived primitive macrophage precursors (iPMPs) and iPSC-derived microglia (iMG) cluster with
primary microglia cultured in vitro (In vitro MG (2)).
(B) When compared using a subset of genes enriched in murine microglia over other CNS myeloid cells (Bennett et al., 2016), iMG and
iPMPs again cluster with primary microglia cultured in vitro (In vitro fetal MG [fMG], In vitro MG (1), and In vitro MG (2)), and additionally
with an alternative iMG method (Alternate iMG; Abud et al., 2017) and monocyte-derived macrophages (MDM).
(C) FPKM (fragments per kilobase million) counts of ‘‘microglia signature’’ genes indicate comparable levels of expression in iMG compared
with in vitro and ex vivo primary microglia. Monocytes, CD14+/CD16 monocytes (Abud et al., 2017); MDM, monocyte-derived macro-
phages (Zhang et al., 2015); iPMPs, iPSC-derived primitive macrophage precursors (this study); iMG, iPSC-derived microglia (this study);
iMG (alternate), iPSC-microglia derived using an alternative method (Abud et al., 2017); In vitro fMG, in vitro fetal microglia (Abud et al.,
2017); In vitro MG (1), in vitro microglia (Abud et al., 2017); In vitro MG (2), in vitro microglia (Gosselin et al., 2017); Ex vivo MG/Mac,
primary sorted CNS CD45+ microglia/macrophages (Zhang et al., 2016); Ex vivo MG, primary sorted microglia (Gosselin et al., 2017). For
iPMPs and iMG, n = 3 independent differentiations of 2 genetic backgrounds (n = 5 iPMPs, n = 6 iMG).
In (A) and (B), genetic backgrounds of iPMPs and iMG are distinguished by square and triangle symbols. For (C), iMG FPKM values were
averaged across differentiations to give values for each genetic background (n = 2). Error bars represent SDs.
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Figure 3. Stem Cell-Derived Microglia Are
Functionally Similar to Primary Microglia
(A) Microglia efficiently phagocytose
pHrodo-E. coli, in a process sensitive to
cytochalasin D.
(B) Upon exposure to 100 ng/mL LPS,
microglia secrete pro-inflammatory cyto-
kines; an effect augmented by interferon g
(IFN-g).
(C) Microglia migrate into preformed
cortical organoids. Upon migration, micro-
glia tessellate throughout organoids and
assume a pronounced ramified morphology,
which is demonstrated by live 2-photon
imaging of organoid/microglia co-cultures.
Scale bars represent 200 mm (A) and 100 mm
(C), while scale grid markings at high
magnification represent 12.4 mm. In (B),
n = 3 biological replicates; * p < 0.05, ** p <
0.01 treatment versus control; Dunnett’s
post hoc test. Error bars represent SDs.Expression of Mutant TREM2 in Stem Cell-Derived
Microglia
To study the function and dysfunction of TREM2 in micro-
glia, we investigated themost severe form of TREM2 disrup-
tion in humans, that of the missense mutations causing
FTD-like syndrome and NHD. We obtained fibroblasts
from a patient homozygous for the TREM2 T66Mmutation,
associated with an FTD-like condition (Guerreiro et al.,
2013b) (T66M/T66M), two unaffected family members car-
rying a single copy of the T66Mmutation (wt/T66M), and a
patient homozygous for the recently described TREM21298 Stem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018W50C mutation causal for NHD (Dardiotis et al., 2017)
(W50C/W50C), and reprogrammed them to iPSCs. After
characterizing iPSC lines (Figures S1–S3),we confirmed their
capacity to differentiate into microglia by expression of a
number of microglia-enriched genes (Figure S4).
In heterologous cell systems, it has been demonstrated
that missense mutations in the TREM2 gene disrupt intra-
cellular trafficking and protein maturation of TREM2, ulti-
mately reducing functional cell surface expression and ec-
todomain shedding (Kleinberger et al., 2014; Kober et al.,
2016; Park et al., 2015). We sought to determine if cell
Figure 4. The TREM2 Receptor Is Mislocalized and Aberrantly Processed in TREM2 Mutant Microglia
(A) Staining for the TREM2 receptor with an N-terminally directed primary antibody reveals expression of TREM2 protein in microglia from
TREM2 wild-type and mutant microglia when cells are permeabilized. Upon omission of permeabilization, TREM2 receptor surface staining
is only detected in TREM2 wild-type and heterozygous mutant microglia, and is absent in microglia derived from homozygous mutant
backgrounds.
(B) Probing of whole-cell lysates reveals expression of immature and mature forms of the full-length (F/L) TREM2 receptor in wild-type
microglia. Mutations in TREM2 cause a gene-dosage-dependent accumulation of immature TREM2, and a reduction in mature forms of
TREM2.
(C) Probing with a C-terminally directed antibody reveals a weak band corresponding to the CTF of TREM2 in wild-type microglia, indicating
efficient turnover of the CTF. Overnight treatment with DAPT (10 mM) results in accumulation of the TREM2-CTF in TREM2 wild-type mi-
croglia, a barely detectable accumulation in heterozygous mutant microglia and no detectable accumulation in homozygous mutant
microglia.
Scale bar represents 50 mm.surface expression, maturation, and proteolysis of TREM2
was impaired in microglia harboring missense mutations
in TREM2 (Figure 4). Using an N-terminal antibody against
the extracellular ectodomain of TREM2, we performed
immunofluorescence with or without permeabilization of
the plasma membrane (Figure 4A). With permeabilization,
TREM2 protein was detected in wild-type microglia, as well
as microglia from heterozygous (wt/T66M) and homozy-gous (T66M/T66M and W50C/W50C) TREM2 mutant
backgrounds. In the absence of permeabilization, plasma
membrane TREM2 was only detected in wild-type and het-
erozygous (wt/T66M) TREM2 backgrounds, indicating a
loss of functional receptor surface expression in homozy-
gous TREM2 mutant microglia.
Western blot analysis of whole-cell lysates indicated that
TREM2 wild-type microglia express both mature andStem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018 1299
immature forms of TREM2, but there is a gene dosage-
dependent reduction in mature forms and a concomitant
increase in immature forms of TREM2 in mutant microglia
(Figure 4B), indicating mutation-dependent effects on pro-
tein maturation. Full-length TREM2 undergoes regulated
intramembrane proteolysis (RIP) by the metalloproteases
ADAM17 and ADAM10 (Feuerbach et al., 2017; Kleinberger
et al., 2014), which releases a soluble TREM2 fragment and
leaves a membrane-bound C-terminal fragment (CTF) that
is a substrate for the g-secretase complex (Wunderlich et al.,
2013). To determine the effects of missense mutations on
TREM2 RIP, we probed whole-cell lysates with a C-termi-
nally directed TREM2 protein antibody. In the steady state,
TREM2-CTF is barely detectable in wild-type microglia,
indicating rapid turnover by g-secretase (Figure 4C).
Following treatment with a g-secretase inhibitor (DAPT),
the levels of TREM2 CTF increase in TREM2 wild-type mi-
croglia, but are barely detectable in heterozygous (wt/
T66M) and not detectable in homozygous (T66M/T66M
and W50C/W50C) TREM2 mutant microglia, indicating
reduced proteolysis of TREM2, most likely due to reduced
cell surface expression and shedding of soluble TREM2.
We conclude that the consequences of both TREM2
missense mutations are complex: there is no detectable
TREM2 on the plasma membrane, a reduction in matura-
tion of the TREM2 protein, and reduced generation of the
CTF of TREM2. While FTD-like and NHD mutations have
been described as loss-of-function mutations, they are
not all alike. Nonsense mutations such as Q33X result in
a truncated protein, whereas missense mutations such as
T66M (and possibly W50C (Dardiotis et al., 2017)) result
in aberrant trafficking and either loss of expression or
expression of misfolded and non-functional protein on
the cell surface (Kleinberger et al., 2014; Kober et al.,
2016). In that respect, missense mutations in TREM2 may
not be the equivalent of simple loss-of-functionmutations,
and may have complex downstream effects on interacting
partners and intracellular trafficking machinery.
TREM2 Mutant Microglia Respond Appropriately
to Pathogenic Challenge
It has been reported that TREM2 modulates inflammatory
responses to pathogenic stimuli (Ito and Hamerman,
2012; Turnbull et al., 2006). We exposed microglia from
TREM2 wild-type and mutant backgrounds to LPS, and
measured the release of IL-1b, IL-6, and TNF-a in the extra-
cellular medium after 6 hr (Figure 5A). Two-way ANOVA
revealed that, while LPS concentration had a significant ef-
fect on the release of IL-1b (F(3, 12) = 16.94, p = 0.0001), IL-6
(F(3, 12) = 133.5, p = < 0.0001), and TNF-a (F(3, 12) = 21.73,
p = < 0.0001), there was no significant effect of genotype
on cytokine release, and no significant interaction between
LPS concentration and genotype. To assess whether clonal1300 Stem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018differences in reprogrammed iPSC lines might contribute
to the observed lack of effect of TREM2 mutations on
response to LPS, we performed further experiments on mi-
croglia differentiated from two additional clones of T66M/
T66M mutant iPSCs. Again, we found that TREM2 mutant
microglia released similar levels of cytokines to TREM2
wild-typemicroglia in response to LPS (Figure 5B). This indi-
cates that TREM2 mutant microglia have a normal physio-
logical response to pathological stimuli in this system.
TREM2 Mutant Microglia Are Phagocytically
Competent
As TREM2 has a proposed role in phagocytosis, we sought
to determine if missense mutations in this gene had a sig-
nificant effect on microglia clearance of bacterial particles.
Live imaging over 2 hr with pHrodo-E. coli particles re-
vealed that microglia from wild-type TREM2 backgrounds
efficiently phagocytose bioparticles (Figures 6A and 6B).
While one-way ANOVA of the 2 hr area under curve
(AUC) indicated differences between treatment and geno-
type groups (F(2, 5) = 13.42, p = 0.0098), Dunnett’s post
hoc testing revealed that TREM2 wild-type microglia
phagocytosis was significantly inhibited by cytochalasin
D (p = 0.0111, compared with untreated TREM2 wild-
type microglia); however, microglia differentiated from
T66M/T66M and W50C/W50C TREM2 mutant back-
grounds phagocytosed bioparticles as efficiently as micro-
glia from wild-type TREM2 backgrounds (p = 0.9519,
compared with untreated TREM2 wild-type microglia).
Ourmicrogliamediumcontains serum,which is known to
opsonize and enhance phagocytic mechanisms. To investi-
gate whether serum could mask potential deficits in phago-
cytosis, we repeated E. coli-uptake experiments in the
absenceof serum, followingovernight serumstarvation (Fig-
ures 6C and 6D). In serum-starved conditions, microglia
again phagocytosed E. coil particles, although notably at a
slower rate than in serum-containing conditions. One-way
ANOVA of the 3 hr AUC indicated a difference between
groups (F(3, 6) = 18.03, p = 0.0021), which Dunnett’s post
hoc testing revealed was driven by a reduced particle uptake
in cytochalasin D-treated TREM2 wild-type microglia (p =
0.0042, compared with untreated TREM2 wild-type micro-
glia);however,nodifferences inuptakecomparingheterozy-
gous or homozygous TREM2mutant microglia with TREM2
wild-typemicroglia (p = 0.3212 and p = 0.9361, respectively,
compared with untreated wild-type TREM2microglia).
In addition to its proposed role as a phagocytosis recep-
tor, TREM2 has been demonstrated to be an uptake recep-
tor for number of proteins, including acetylated LDL
(AcLDL) (Yeh et al., 2016). To assess the uptake of AcLDL
in microglia, and the consequences of TREM2 mutations,
microglia from TREM2 wild-type and homozygous mutant
backgrounds were exposed to labeled AcLDL and assessed
Figure 5. Microglia Harboring TREM2 Mutations Respond Appropriately to LPS Challenge
(A) Upon exposure to LPS, microglia from TREM2 wild-type and mutant backgrounds release pro-inflammatory cytokines in a dose-
dependent manner.
(B) Further experiments in two additional clones from patient T66M/T66M confirm a similar response to LPS challenge across all clones of
this genotype.
Results in (A) are an average of all data from two independently performed treatments, n = 2 biological replicates per genotype and error
bars represent SDs. Error bars in (B) represent SE of 2–3 technical well replicates, and x-axis values are LPS concentration in pg/mL.30 min and 3 hr post exposure for internalized AcLDL
(Figures 6E–6G). Two-way ANOVA revealed a statistically
significant effect of genotype (F(1, 6) = 7.28, p = 0.0357)
on the uptake of AcLDL; however, there was no interaction
between genotype and time point (F(1, 6) = 0.5492, p =
0.4866), and the effect between genotypes was not signifi-
cant at either time point alone (p = 0.3848 and p = 0.0995 at
30min and 3 hr, respectively), or when compared using the
3 hr uptake AUC (t(3) = 2.104, p = 0.1261), indicating a mi-
nor impairment of AcLDL uptake in TREM2 homozygous
mutant microglia, consistent with the presence of a
number of scavenger receptors for AcLDL in addition to
TREM2 (Canton et al., 2013).DISCUSSION
We describe the derivation and characterization of micro-
glia from human stem cells, which transcriptionally and
functionally resemble primary microglia. Using these cellsas a model for microglial biology, we probed the conse-
quences of TREM2 mutations using microglia derived
from patients carrying missense mutations in TREM2 caus-
ative for the neurodegenerative conditions FTD-like syn-
drome and NHD. We found that TREM2 is aberrantly pro-
cessed in microglia from TREM2 mutant backgrounds,
accumulating in its immature form, and, furthermore, is
not trafficked appropriately to the cell membrane in homo-
zygousmutantmicroglia. Unexpectedly, despite dysregula-
tion of TREM2 protein expression, mutantmicroglia differ-
entiate properly, effectively respond to pathogenic stimuli,
and phagocytose appropriately.
Microglia originate from PMPs that invade the devel-
oping CNS and mature into microglia (Ginhoux et al.,
2010, 2013). To reproduce the developmental origin of mi-
croglia, we began with a protocol for the generation of
PMPs (Karlsson et al., 2008; van Wilgenburg et al., 2013).
These precursors are not dependent on the transcription
factorMyb (Buchrieser et al., 2017), and are therefore closer
in lineage to yolk-sac-derived precursors of microglia thanStem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018 1301
Figure 6. Microglia from TREM2 Mutant
Backgrounds Are Phagocytically Compe-
tent
(A and B) Homozygous TREM2 mutant mi-
croglia phagocytose pHrodo-E. coli with a
similar efficiency and capacity to microglia
from a wild-type background. In contrast,
cytochalasin D significantly attenuates
pHrodo-E. coli uptake.
(C and D) Similarly, after serum starvation,
TREM2 mutant microglia phagocytose E. coli
as efficiently as TREM2 wild-type microglia.
(E–G) TREM2 mutant microglia internalize
AcLDL almost as efficiently as TREM2 wild-
type microglia.
Scale bar represents 200 mm. All data from
two (C, D, and E–G) or three (A and B) in-
dependent experiments were averaged to
produce values for each genotype. n = 3
(TREM2 wild-type-untreated; TREM2 wild-
type cytochalasin D-treated) or 2 (TREM2
heterozygous; TREM2 homozygous) biolog-
ical replicates. *p < 0.05, **p < 0.01
versus untreated TREM2 wild-type microglia,
Dunnett’s post hoc test. n.s., not significant.
Error bars represent SDs.Myb-dependent precursors of the definitive hematopoiesis
pathway (Schulz et al., 2012). Using IL-34, which is pro-
duced by neurons in the developing CNS, and is essential
for microglial development and survival (Wang et al.,
2012), together with GM-CSF, we matured these macro-
phage precursors into microglia. The entire protocol is
rapid and efficient, producingmicroglia that express a tran-
scriptional and functional signature comparable with pri-
mary human microglia within 4 weeks. Over the course
of this study, a number of microglia differentiation proto-
cols were reported (Abud et al., 2017; Douvaras et al.,
2017; Haenseler et al., 2017; Muffat et al., 2016; Pandya1302 Stem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018et al., 2017). This method compares favorably with these
recent studies, with a simple, sorting-free protocol that
yields comparable numbers of microglia over a similar
timescale (Abud et al., 2017; Haenseler et al., 2017), and a
comparable transcriptome with the microglia described
by Abud et al. (2017), which relies on a much more com-
plex differentiation method.
The transcriptional signature associated with microglial
identity is rapidly lost upon removal from the neural envi-
ronment, making isolated culture of microglia challenging
(Bohlen et al., 2017; Gosselin et al., 2017). While efforts
have been made to understand the environmental cues
driving microglial identity (Bohlen et al., 2017; Butovsky
et al., 2014), there are still gaps in our knowledge regarding
how medium composition can influence the transcrip-
tome, as further demonstrated in this study, which indi-
cates a clear separation between freshly isolated ex vivo
and in vitro cultured microglia, even between samples
from the same individual (Gosselin et al., 2017). Expression
of the microglia-enriched gene TMEM119, for example, is
particularly strongly downregulated in microglia removed
from the CNS (Gosselin et al., 2017). The presence of serum
in microglial maintenance medium has been reported to
induce expression of this gene (Douvaras et al., 2017), how-
ever, perhaps explaining why some TMEM119 expression
is observed in our microglia, but not those derived in
another study that used defined conditions (Abud et al.,
2017). While the use of serum has some drawbacks,
including introducing potential variability into differentia-
tion efficiency, we have shown, both transcriptionally and
by expression of the macrophage/microglial markers Iba1,
CD45, and TREM2, that our differentiation protocol is
consistent in efficiency across genetic backgrounds, indi-
cating an acceptable level of variability for studying micro-
glial biology and pathophysiology.
Missense mutations in TREM2 are thought to affect pro-
tein structure, leading to trafficking defects and reduced
cell surface expression. We have determined that the
FTD-like mutation T66M results in protein mis-processing
and reduced surface expression of TREM2 in stem cell-
derivedmicroglia, as was previously demonstrated in heter-
ologous cell systems (Kleinberger et al., 2014; Kober et al.,
2016; Park et al., 2015). Likewise, the recently identified
NHD mutation W50C results in similar mis-regulation, as
was predicted by structural modeling (Dardiotis et al.,
2017). As TREM2 is postulated to regulate the innate im-
mune system, and is thought to directly modulate phago-
cytosis and responses to pathogens, we chose to investigate
these functions in patient-derived microglia from these
TREM2 mutant backgrounds, and found, surprisingly,
that these functions remained intact even in presumed
loss-of-function TREM2 backgrounds.
When TREM2 is overexpressed in non-phagocytic cells,
it confers phagocytic activity (Kleinberger et al., 2014;
N’Diaye et al., 2009). Likewise, in murine macrophages
and microglia, genetic disruption of TREM2 has been re-
ported to impair the uptake of synthetic material, bacteria,
and apoptotic neurons (Hsieh et al., 2009; Kleinberger
et al., 2017; Kleinberger et al., 2014; N’Diaye et al., 2009; Ta-
kahashi et al., 2005), although this has not always been
observed (Wang et al., 2015). It is perhaps surprising that
we did not observe impaired phagocytosis in TREM2
mutant microglia, although the impact of TREM2 disrup-
tion on phagocytosis has not previously been demon-
strated in human phagocytes expressing physiologicallevels of TREM2 protein. It is possible that the wide range
of phagocytic receptors in microglia (Sierra et al., 2013)
acts to compensate for a loss of TREM2, thus masking any
potential impairment. Similarly, for the uptake of AcLDL,
which we demonstrated is only mildly impaired in micro-
glia derived from TREM2 mutant backgrounds compared
with wild-type backgrounds, there are many receptors
that potentially internalize ligands of TREM2, making it
difficult to establish a deficit due to loss of function of
TREM2 alone. TREM2 has also been demonstrated as a
modulator of TLR signaling (Ito and Hamerman, 2012;
Turnbull et al., 2006; Wang et al., 2015). While we did
not observe differential responses of TREM2mutantmicro-
glia to the TLR4 ligand LPS, it is known that effects of
TREM2 on innate immune responses are variable, and
depend upon ligand, cell type, and model system (Ito and
Hamerman, 2012; Kang et al., 2018; Turnbull et al.,
2006). It is possible that TREM2 has more subtle or
context-dependent roles in microglial immune regulation
that will require more complex culture conditions to inves-
tigate (Keren-Shaul et al., 2017; Krasemann et al., 2017).
In summary, this report details the utility of a simple and
effective method for generating microglia from human
stem cells. Microglia differentiated from patients carrying
missense mutations in TREM2 that are causal for FTD-like
syndrome andNHD accumulate immature TREM2 protein,
and do not express functional TREM2 on the cell surface.
Despite aberrant TREM2 processing, microglia from
mutant TREM2 backgrounds respond appropriately to
challenge with pathogens, releasing similar levels of in-
flammatory cytokines and phagocytosing as efficiently as
TREM2 wild-type microglia. These results suggest a com-
plex and subtle effect of missense TREM2mutations onmi-
croglial function that may take some time to manifest in
the clinical symptoms, in line with the adult onset of de-
mentia in FTD-like syndrome and NHD.EXPERIMENTAL PROCEDURES
See Supplemental Information for full details of all methods used.Microglia Differentiation
Details of PSC lines used in this study can be found in Supple-
mental Experimental Procedures. TREM2mutant lines were gener-
ated from fibroblasts derived from skin punch biopsies obtained
following informed consent, after approval from the ethics com-
mittee of the Istanbul Faculty of Medicine, Istanbul University,
or the joint research ethics committee of the National Hospital
for Neurology and Neurosurgery and the Institute of Neurology,
UCL. Microglia were differentiated from PSCs via embryoid bodies
and PMPs (Karlsson et al., 2008; van Wilgenburg et al., 2013). In
brief, at least 2 days after last passaging, PSCs (cultured feeder-
free in E8) were passaged to single cells with TrypLE ExpressStem Cell Reports j Vol. 10 j 1294–1307 j April 10, 2018 1303
(Gibco), and plated at 10,000 per well in 96-well ultra-low attach-
ment plates (Corning) in 100 mL embryoid body medium (10 mM
ROCK inhibitor, 50 ng/mL BMP-4, 20 ng/mL SCF, and 50 ng/mL
VEGF-121 in E8), before centrifugation at 300 3 g for 3 min.
Embryoid bodies were cultured for 4 days, with half medium
change after 2 days. Ten to 16 embryoid bodies were plated per
well of tissue culture-treated 6-well plates and cultured in 3 mL
hematopoetic medium (2 mM GlutaMax, 100 U/mL penicillin,
100 mg/mL streptomycin, 55 mM b-mercaptoethanol, 100 ng/mL
M-CSF, and 25 ng/mL IL-3 in X-VIVO 15 [Lonza, LZBE02-060F]).
From this point on, 2 mL medium was exchanged every 4–7 days.
PMPs were harvested from suspension duringmedium exchange
and plated in RPMI 1640 at 180,000 cells/cm2 in 6-, 12-, or 96-well
plates. In the absence of serum, PMPs adhered to uncoated tissue
culture-treated plastic within 1 hr, at which point medium was
switched to complete microglia medium (10% FBS [Gibco,
16000044 or Sigma, [F2442], 2 mM GlutaMax, 100 U/mL peni-
cillin, 100 mg/mL streptomycin, 100 ng/mL IL-34, and 10 ng/mL
GM-CSF in RPMI1640).
Final differentiation of PMPs into microglia occurred over
6–10 days, with full medium change every 2–3 days. All cytokines
and growth factors obtained from PeproTech, except for IL-3 (Cell
Guidance Systems).
Statistical Analysis
Statistical analysis was performed in GraphPad Prism 7. Indepen-
dent genetic backgrounds were considered biological replicates,
with wells, treatments, or experiments averaged as technical repli-
cates. TREM2 genotypes (wild-type, heterozygous, or homozygous
for NHD/FTD-like mutations) were grouped for analysis. While ge-
notype n numbers were low, and tests for normality and distribu-
tion thus of limited value, this was not considered an impediment
to parametric analysis (De Winter, 2013).
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